From Moderna to Dash Bio - Revolutionizing Drug Development with Dave Johnson

We've got a very exciting episode of Data in Biotech to share.

Ross Katz sat down with Dave Johnson - former Chief Data and Artificial Intelligence Officer at Moderna and now CEO and Co-founder of Dash Bio - to talk about how his new venture is set to revolutionize clinical bioanalysis and streamline drug development.

Dave takes us back to the early research days in Moderna, where he helped lay the groundwork for mRNA technology, which later enabled the development of a vaccine for COVID-19 at unprecedented speed.

He also highlights what he sees as the most impactful insufficiencies in drug development—particularly the lack of industrialization and standardization— and how Dash Bio aims to address these issues.

The goal— he tells us—is ultimately to develop a more efficient, high-quality end-to-end system and improve the overall efficacy of the drug development process.

Ross and Dave also touch upon Dave’s vision for the future of Dash Bio, plus his advice for aspiring biotech data leaders eager to contribute to industry transformation.

Listen wherever you get your podcasts.

Apple: https://lnkd.in/d8BDwZ9Q

Spotify: https://lnkd.in/dtG7GRRK